financetom
Business
financetom
/
Business
/
Jabil Poised for Multiyear Growth Cycle Driven by AI Investments, Rising Demand, UBS Securities Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Jabil Poised for Multiyear Growth Cycle Driven by AI Investments, Rising Demand, UBS Securities Says
Aug 11, 2026 9:42 AM

12:10 PM EDT, 08/11/2026 (MT Newswires) -- Jabil ( JBL ) is poised for a multiyear growth cycle driven by artificial intelligence investments, rising healthcare demand as capacity from the Croatia site comes online, and scaling automation and robotics markets, UBS said in a note Monday.

The investment firm said that while its base case estimates Jabil's ( JBL ) AI-related revenue to grow at least 50% in 2027 to about $20.3 billion, recent checks show capacity expansion in Memphis and North Carolina markets along with product road maps at key customers support potentially faster growth than previously expected.

Additionally, the company's Croatia facility should accelerate revenue growth and drive operating margin expansion in 2028 through a mix of higher margin products like GLP-1s and volume leverage as capacity is absorbed over the coming quarters, according to the note.

Jabil ( JBL ) shifting its portfolio toward markets like automation is a plus for its growth and margins, the investment firm said, adding that it expects Jabil ( JBL ) to continue to invest in end-markets that lift growth, margins, and ROI, suggesting operating margin could exceed 6% in fiscal 2027.

UBS Securities upgraded its rating on the company's stock to buy from neutral, and maintained its $430 price target.

Shares of Jabil ( JBL ) were up more than 4% in Tuesday trading.

Price: 351.49, Change: +14.86, Percent Change: +4.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cineplex Launches 'Monday Surprise Premieres' From Nov. 10
Cineplex Launches 'Monday Surprise Premieres' From Nov. 10
Oct 27, 2025
07:56 AM EDT, 10/27/2025 (MT Newswires) -- Cineplex ( CPXGF ) said Monday it is launching its Monday Surprise Premieres, a special event featuring an exclusive mystery screening of a major new release from Nov. 10. Tickets are priced at $8.99 (in-theatre price) and Cineclub members can use their free monthly ticket for this event, a statement said. ...
Gogo Says SD Government Division Awarded 5-Year US Federal Contract
Gogo Says SD Government Division Awarded 5-Year US Federal Contract
Oct 27, 2025
07:53 AM EDT, 10/27/2025 (MT Newswires) -- Gogo ( GOGO ) said Monday its SD Government division was awarded a five-year contract to supply airborne satellite communications to a US government agency, initially valued at $3 million. The contract is a follow-on from the phase 3 activity of the Small Business Innovation Research program, originally undertaken by SD Government before...
Top Premarket Decliners
Top Premarket Decliners
Oct 27, 2025
07:53 AM EDT, 10/27/2025 (MT Newswires) -- Genenta Science (GNTA) shares were nearly 35% lower pre-bell Monday after the company priced overnight a $15 million registered direct offering of American depositary shares. MaxsMaking ( MAMK ) stock was down 23%, paring gains from the previous session. United States Antimony ( UAMY ) shares were 15% lower after Friday's 2.4% gain....
Elanco Animal Health Says FDA Approves Expanded Labels for Credelio, Credelio Quattro
Elanco Animal Health Says FDA Approves Expanded Labels for Credelio, Credelio Quattro
Oct 27, 2025
07:51 AM EDT, 10/27/2025 (MT Newswires) -- Elanco Animal Health ( ELAN ) said Monday the US Food and Drug Administration has approved expanded labels for its Credelio and Credelio Quattro parasiticides to include prevention of Lyme disease and treatment and control of longhorned tick infestations in dogs. The company said both products showed 100% efficacy against longhorned ticks in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved